MCID: TRP003
MIFTS: 23

Triple-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Triple-Receptor Negative Breast Cancer

MalaCards integrated aliases for Triple-Receptor Negative Breast Cancer:

Name: Triple-Receptor Negative Breast Cancer 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0060081

Summaries for Triple-Receptor Negative Breast Cancer

Disease Ontology : 12 A breast cancer that is characterized by the absence of estrogen, progresterone and Her2 receptors.

MalaCards based summary : Triple-Receptor Negative Breast Cancer is related to breast cancer and ovarian epithelial cancer. An important gene associated with Triple-Receptor Negative Breast Cancer is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Pembrolizumab and Antineoplastic Agents, Immunological have been mentioned in the context of this disorder. Affiliated tissues include brain and breast.

Related Diseases for Triple-Receptor Negative Breast Cancer

Diseases related to Triple-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 30)
# Related Disease Score Top Affiliating Genes
1 breast cancer 10.6
2 ovarian epithelial cancer 10.1 HOTAIR MALAT1
3 pituitary adenoma 10.1 HOTAIR MALAT1
4 laryngeal squamous cell carcinoma 10.1 HOTAIR MALAT1
5 pancreatic ductal adenocarcinoma 10.1 HOTAIR MALAT1
6 gastrointestinal system cancer 10.1 HOTAIR MALAT1
7 kidney cancer 10.1 HOTAIR MALAT1
8 osteogenic sarcoma 10.0 HOTAIR MALAT1
9 spindle cell carcinoma 10.0
10 small cell cancer of the lung 10.0 HOTAIR MALAT1
11 oral squamous cell carcinoma 10.0 HOTAIR MALAT1
12 bladder urothelial carcinoma 10.0 HOTAIR MALAT1
13 b-cell lymphomas 10.0 HOTAIR MALAT1
14 liver cirrhosis 9.9 HOTAIR MALAT1
15 myeloma, multiple 9.9 HOTAIR MALAT1
16 pre-eclampsia 9.9 HOTAIR MALAT1
17 retinoblastoma 9.8 HOTAIR MALAT1
18 thyroid cancer, nonmedullary, 1 9.7 HOTAIR LINC-ROR MALAT1
19 gallbladder cancer 9.7 HOTAIR LINC-ROR MALAT1
20 adamantinoma of long bones 9.7 HOTAIR LINC-ROR MALAT1
21 renal cell carcinoma, nonpapillary 9.7 HOTAIR LINC-ROR MALAT1
22 nasopharyngeal carcinoma 9.7 HOTAIR LINC-ROR MALAT1
23 lung cancer susceptibility 3 9.7 HOTAIR LINC-ROR MALAT1
24 melanoma 9.7 HOTAIR LINC-ROR MALAT1
25 esophageal cancer 9.7 HOTAIR LINC-ROR MALAT1
26 pancreatic cancer 9.7 HOTAIR LINC-ROR MALAT1
27 ovarian cancer 9.6 HOTAIR LINC-ROR MALAT1
28 gastric cancer 9.6 HOTAIR LINC-ROR MALAT1
29 lung cancer 9.4 HOTAIR LINC-ROR MALAT1 PCAT6
30 hepatocellular carcinoma 9.3 HOTAIR LINC-ROR MALAT1

Graphical network of the top 20 diseases related to Triple-Receptor Negative Breast Cancer:



Diseases related to Triple-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Triple-Receptor Negative Breast Cancer

Drugs & Therapeutics for Triple-Receptor Negative Breast Cancer

Drugs for Triple-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pembrolizumab Approved Phase 3 1374853-91-4
2 Antineoplastic Agents, Immunological Phase 3,Phase 2
3
Epirubicin Approved Phase 2 56420-45-2 41867
4
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
5
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
6
Fluorouracil Approved Phase 2 51-21-8 3385
7
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
8
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
9
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
10
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
11
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
12
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
13
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
14
Gemcitabine Approved Phase 2 95058-81-4 60750
15
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
16
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
17 Anti-Infective Agents Phase 2
18 Antimetabolites Phase 2
19 Immunosuppressive Agents Phase 2
20 Anti-Bacterial Agents Phase 2
21 Antineoplastic Agents, Alkylating Phase 2
22 Antimetabolites, Antineoplastic Phase 2
23 Immunologic Factors Phase 2
24 Topoisomerase Inhibitors Phase 2
25 Albumin-Bound Paclitaxel Phase 2
26 Alkylating Agents Phase 2
27 Antibiotics, Antitubercular Phase 2
28 Antimitotic Agents Phase 2
29 Antineoplastic Agents, Phytogenic Phase 2
30 Antifungal Agents Phase 2
31 Antirheumatic Agents Phase 2
32 Mitogens Phase 2
33 Antibodies Phase 2
34 Immunoglobulins Phase 2
35 Antibodies, Monoclonal Phase 2
36 taxane Phase 2
37
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
38 Protein Kinase Inhibitors Phase 2
39 Angiogenesis Inhibitors Phase 2
40 Angiogenesis Modulating Agents Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3
2 Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer Unknown status NCT00499603 Phase 2 Paclitaxel;5-Fluorouracil;Epirubicin;Cyclophosphamide;RAD001
3 Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer Recruiting NCT03692689 Phase 2
4 EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients Completed NCT00448305 Phase 2 EndoTAG-1 + paclitaxel;EndoTAG-1;Paclitaxel
5 Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer Terminated NCT00739063 Phase 2 Tarceva
6 Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Not yet recruiting NCT03756298 Phase 2 Atezolizumab;Capecitabine
7 A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations Terminated NCT02299635 Phase 2 PF-03084014;PF-03084014;PF-03084014
8 Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer Completed NCT00246571 Phase 2 SU011248;Chemotherapy
9 An Phase Ib Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) Not yet recruiting NCT03855358 Phase 1 TQB2450 Injection and Anlotinib Hydrochioride Capsules

Search NIH Clinical Center for Triple-Receptor Negative Breast Cancer

Genetic Tests for Triple-Receptor Negative Breast Cancer

Anatomical Context for Triple-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Triple-Receptor Negative Breast Cancer:

42
Brain, Breast

Publications for Triple-Receptor Negative Breast Cancer

Articles related to Triple-Receptor Negative Breast Cancer:

(show all 12)
# Title Authors Year
1
Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. ( 29235566 )
2018
2
The unmet need for effective treatment of triple-receptor negative breast cancer. ( 25768894 )
2014
3
Mesothelin expression and survival outcomes in triple receptor negative breast cancer. ( 23810431 )
2013
4
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. ( 21800293 )
2012
5
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. ( 22359359 )
2012
6
Triple receptor-negative breast cancer: imaging and clinical characteristics. ( 22826413 )
2012
7
Capecitabine in operable triple receptor-negative breast cancer: A subgroup analysis of a randomized phase III trial. ( 27958045 )
2011
8
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. ( 21233401 )
2011
9
Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? ( 20580045 )
2010
10
Survival among women with triple receptor-negative breast cancer and brain metastases. ( 19150943 )
2009
11
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. ( 19047281 )
2009
12
Advances in triple receptor-negative breast cancer. ( 18277956 )
2007

Variations for Triple-Receptor Negative Breast Cancer

Expression for Triple-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Triple-Receptor Negative Breast Cancer.

Pathways for Triple-Receptor Negative Breast Cancer

Pathways related to Triple-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 HOTAIR LINC-ROR

GO Terms for Triple-Receptor Negative Breast Cancer

Sources for Triple-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....